Nuvalent/$NUVL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nuvalent

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Ticker

$NUVL
Sector
Primary listing

Employees

200

Nuvalent Metrics

BasicAdvanced
$5.5B
-
-$4.90
1.30
-

What the Analysts think about Nuvalent

Analyst ratings (Buy, Hold, Sell) for Nuvalent stock.

Bulls say / Bears say

Nuvalent reported a cash position of $1.0 billion as of June 30, 2025, expecting this to fund operations through 2028, which supports advancing multiple clinical programs without needing further financing soon. (PR Newswire)
The ARROS-1 trial of zidesamtinib showed a 44% objective response rate and an estimated 78% durability of response at 12 months in TKI-pre-treated ROS1-positive NSCLC patients, supporting the drug’s best-in-class potential. (PR Newswire)
Nuvalent started a rolling NDA submission for zidesamtinib in July 2025 and dosed the first patient in the ALKAZAR Phase 3 trial of NVL-655 for front-line ALK-positive NSCLC in the first half of 2025, showing ongoing regulatory progress and clinical trial momentum. (PR Newswire)
Nuvalent’s net loss increased to $99.7 million in Q2 2025 with EPS of -$1.39, missing analyst estimates, pointing to significant cash burn and potential pressure on financial flexibility. (GuruFocus)
Analysts have warned that Nuvalent may be overvalued at current share price levels even after UBS raised its price target, suggesting there could be limited upside and a risk of a market correction despite strong trial data. (Investing.com)
The HER2-selective inhibitor NVL-330 is still in Phase 1 with only safety and dose-escalation data available, reflecting a lack of near-term pipeline diversification and ongoing dependence on lead programs to drive value. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Nuvalent Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Nuvalent Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NUVL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs